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Abstract 
Review on Breast implant-associated anaplastic 
large cell lymphoma with clinics and the genes 
involved 
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Identity 
Other names 
Seroma-associated anaplastic large cell lymphoma 
Clinics and pathology 
Disease 
Breast implant-associated anaplastic large cell 
lymphoma (BI-ALCL) is a new provisional entity 
described in the 2017 revision of the World Health 
Organization Classification of Tumors of 
Hematopoietic and Lymphoid Tissues (Swerdlow 
SH et al., 2016). This disorder represents an 
uncommon form of slow-growing T-cell lymphoma 
where breast implants play a leading role in the 
lymphomagenesis. For its diagnosis a high index of 
suspicion is warranted.  The most common clinical 
presentation is an effusion around the implant, and 
less common as a tumor mass. (Miranda RN et al., 
2014) Imaging studies, ultrasound specifically, will 
help the clinician diagnose this malignancy (Adrada 
BE, 2014). Further tests are necessary to determinate 
the histologic and immunophenotypic features, 
which are similar to other ALK-negative anaplastic 
large cell lymphomas (ALCLs). The vast majority of 
malignant cells are CD30 positive and ALK-
negative (Quesada AE et al., 2019). Surgery 
represents the optimal approach to the disease, 
reaching excellent results and high rates of overall 
survival (OS). Chemotherapy is reserved for 
systemic cases, and anthracycline-based regimens 
are preferred (Clemens MW, Horwitz SM, 2017). 
Phenotype/cell stem origin 
Immunophenotype is similar to the cell expression of 
systemic ALK-negative ALCLs. Thus is 
characterized by a strong positivity for CD30 and 
negativity for ALK. Several markers like CD43, 
CD45, CD4, TIA-1, granzyme B and EMA are 
frequently expressed; whereas CD3 and CD8 
expression are less prevalent. Epsetin-Barr virus 
small-encoded RNA is constantly negative, like 
CD1a, cyclin D1 and TdT (Quesada AE et al., 2019). 
Etiology 
Pathogenesis is not clearly established, however, 
several mechanisms have been theorized based on 
chronic antigenic stimulation (Laurent C et al., 
2018). This pathway triggers the recruitment, 
expansion, and proliferation of T cells leading to 
clonality and malignant transformation (Roden AC 
et al., 2008). Local inflammation and fibrosis caused 
by the silicone and its degradation products sustain 
T-cell proliferation (Bizjak M et al., 2015). 
Microbiome studies have demonstrated a playing 
role of the gram-negative bacteria Ralostonia 
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pickettii, stimulating Th1 cells by the release of 
cytokines (Hu H et al., 2016). BI-ALCL cells present 
a secretory profile similar to TH1/Th17 cells and are 
dependent on microenvironment cytokines like IL2, 
IL10, and IL6 (De Leval L, 2019). The content of the 
implant (saline or silicone-filled) does not imply an 
increased risk of BI-ALCL (Miranda RN et al., 
2014). However, the different outer shell of the 
implants (textured or smooth) will play a leading role 
in the pathogenesis. Some studies found a higher 
prevalence of BI-ALCL among patents with textured 
implants compared to smooth implants or the general 
population. This difference could be explained by 
the finding in textured implants of inflammation 
with a T-cell profile more frequently than in the 
smooth ones (Meza Britez ME et al., 2012). 
Activation of JAK/STAT3 signaling pathway and 
expression of cytotoxic molecules are also involved 
in the survival and proliferation of BI-ALCL cells 
(Lechner MG et al., 2012). 
Epidemiology 
Non-Hodgkin lymphomas (NHLs) involving the 
breast represent between 1-2% of all NHLs, mostly 
diffuse large B-cell lymphomas (DLBCLs) and 
extranodal marginal zone lymphoma of mucosa-
associated lymphoid tissue (Laurent C et al., 2018). 
On the other hand, ALCLs represent 3% of NHLs 
(Talwalkar SS et al., 2008). BI-ALCL is an 
uncommon neoplasm; although in recent years an 
increase in recognition of this entity has been 
reported. In a meta-analysis, an incidence of fewer 
than 5 cases per 500,000 women with breast 
implants was described (Brody GS et al., 2015). The 
median age of diagnosis is 50 years (De Leval L, 
2019) 
Clinics 
The median time interval from implant surgery to 
lymphoma diagnosis is 8-9 years. Two clinical 
presentations are seen. The vast majority of patients 
(80%) present with an effusion adjoining to the 
implant without extension to the breast parenchyma 
or distance. Necrotic and liquefied lymphoma cells 
are identified on the effusion (Miranda RN et al., 
2014). This malignant seroma could be associated 
with asymmetry, pain or breast swelling. It is 
important to differentiate it from benign fluid 
collections, that could appear early after the surgery 
(De Leval L, 2019). Secondly, the other 20% of 
patients usually present a tumor mass infiltrating 
breast tissue with or without effusion, recognized by 
the patient as a continuous growth of an indurated 
area (Miranda RN et al., 2014). Also, a minority of 
patients (20%) may present with lymph node 
involvement, more frequent axillary in location 
(Ferrufino-Schmidt MC et al., 2018). BI-ALCLs do 
not usually present at diagnosis time with B 
symptoms or skin lesions (Mehta-Shah N et al., 
2018). Two staging systems are routinely used. Ann 
Arbor staging system, being the patients divided in 
stage I (83%), II (10%) and III (7%) at diagnosis 
(Miranda RN et al., 2014). The National 
Comprehensive Cancer Network (NCCN) promotes 
the second one to determinate the degree of tumor 
infiltration into the capsule, a staging system 
proposed by the MD Anderson. Based on a T stage 
included in the clinical Tumor Node Metastasis 
(TNM) solid tumor staging system. In the latter, the 
patients are divided in IA (35.6%), IB (11.5%), IC 
(13.8%), IIA (25.3%), IIB (4.6%), III (9.2%) and IV 
(0-9%) (Clemens MW et al., 2016).  
 Diagnosis The diagnosis of BI-ALCL needs a high 
index of suspicion since it is a low-growth neoplasm 
and its most frequent clinical presentation (effusion) 
could be misdiagnosed as a benign seroma. The 
NCCN has established diagnosis and management 
guidelines that will help diagnosis this disease 
quicker (Clemens MW, Horwitz SM, 2017). An 
exhaustive physical examination has to be performed 
in case of clinical suspicion (fluid collection or 
masses) as well as imaging studies. In peri-prosthetic 
fluid collection cases, the ultrasound achieves the 
best results (sensitivity and specificity of 84% and 
75% respectively), whereas magnetic resonance 
imaging (MRI), computed tomography (CT) and 
mammography are worse in terms of 
sensitivity/specificity in a retrospective study. 
Nevertheless, in tumor masses, PET CT achieved 
better results than MRI, but same as ultrasound 
(Adrada BE, 2014). Once diagnostic of effusion or 
tumor mass is reached, cytological/histological 
examination is necessary. Fine needle aspiration or 
tissue biopsy, depending on the clinical presentation, 
will provide the samples for immunohistochemical 
and histological studies guiding to BI-ALCL 
diagnosis. 
Pathology 
The histological features of BI-ALCL cells resemble 
systemic ALCLs ones. They are large cells with 
anaplastic and pleomorphic morphology, also an 
abundant cytoplasm is founded. The nuclei are large 
or oval, with prominent nucleoli and mitoses 
(Miranda RN et al., 2014). Hallmarks-cells 
encountered in all forms of ALCL are also founded 
on this subtype (specifically in 70% of cases). It is 
defined by an eccentric horseshoe- or kidney-shaped 
nuclei (Swerdlow SH et al., 2016). 
Cytogenetics 
ALK translocations or those involving DUSP22 or 
TP63 that characterize ALK positive large B-cell 
lymphomas and ALK- ALCLs respectively, have not 
been identified in BI-ALCLs (Oishi N et al., 2018). 
However, other molecular genetics findings have 
been reported. Based on Quesada AE et al., review, 
monoclonal TRG and TRB rearrangements are 
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carried by BI-ALCL cells (Quesada AE et al., 2019). 
Furthermore, activating mutations in STAT3 and 
JAK1 have also been described in neoplastic cells, as 
mentioned before being involved in the 
pathogenesis. (Oishi N et al., 2018) 
Treatment 
The treatment of choice depends on the extension of 
the disease. Notwithstanding, complete surgical 
excision, which includes: total capsulectomy and 
removal of the implant and any mass with negative 
margins; represents the optimal approach to all BI-
ALCL (Clemens MW, Horwitz SM, 2017). In 
localized disease (Ann Arbor IE; TNM IA, IIA), the 
NCCN guidelines recommendation is complete 
surgical excision, with no strong role of sentinel 
lymph node biopsy or radical mastectomy. In 
residual localized disease or incomplete excision 
(also including disease with chest wall invasion), 
radiation therapy (24-36 Gy) following surgery is a 
reasonable option (Horwitz SM et al., 2018). It has 
been reported that 4.6% of patients may have 
incidental lymphoma in the contralateral breast, thus 
surgeons may consider the removal of the 
contralateral implant (Clemens MW et al., 2016). In 
systemic disease (Ann Arbor II-IV, TNM IIB-IV) 
systemic therapy is recommended by NCCN 
guidelines. Despite limited data, anthracycline-based 
chemotherapy, like cyclophosphamide, doxorubicin, 
vincristine, prednisone (CHOP) or with the addition 
of etoposide (EPOCH), are usually administrated. 
The use of brentuximab vedotin (anti-CD30 
antibody) has provided responses in systemic 
ALCLs, however further studies are needed in BI-
ALCLs (Vaklavas C, Forero-Torres A, 2012). There 
is no standard guideline for reconstructive surgery, 
and both immediate and delayed reconstruction has 
been done (Mehta-Shah N et al., 2018). 
Prognosis 
BI-ALCLs have a better prognosis than systemic 
ALCL. Stage I patients have a 100% 3-year OS and 
63% EFS (Adrada BE, 2014). A 5-year OS of 98.8% 
has been reported in patients treated with complete 
capsulectomy compared with those cases where it 
was not performed (57.2%) (Clemens MW et al., 
2016). Lymph node involvement confers worse 
prognosis since a 5-year overall survival of 75% for 
those with lymph node involvement has been 
described, compared to a 97.9% in those without.  
Equally, tumor masses affect prognosis since poor 
OS and progression free survival were found 
compared with patients without masses (Adrada BE, 
2014). 
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